Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

293
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
293
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

192
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
192
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

141
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
141
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

168
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
168
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Latissimus Dorsi Flap for Radiation-induced Chest Wall Ulcers.

Plastic and reconstructive surgery. Global open·2026
Same author

Design, synthesis, molecular modeling and anti-cancer activity of novel fluorinated naphtho[2,3-<i>b</i>]thiophene-4,9-dione derivatives.

RSC advances·2026
Same author

Coordination-controlled photophysics and antiproliferative activity of coumarin-linked schiff bases and Zn(II) complexes.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2026
Same author

Simultaneous quantification of donepezil and memantine by HPLC-refractive index detection for novel drug delivery systems.

BMC chemistry·2026
Same author

Methadone Maintenance Treatment-Related Stigma and Adherence Self-Efficacy in Vietnam.

Substance use : research and treatment·2026
Same author

Synthesis, molecular modeling and anti-inflammatory activity of new benzo[<i>a</i>]pyrano[2,3-<i>c</i>]phenazine compounds.

Organic & biomolecular chemistry·2026

Related Experiment Video

Updated: Jan 11, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

781

Pharmaceutical Formulations and Analytical Methods of Donepezil.

Vu Dang Hoang1, Hue Minh Thi Nguyen2, Tuan Anh Nguyen3,4,5

  • 1Faculty of Analytical Chemistry and Drug Quality Control, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi, Vietnam. hoangvd@hup.edu.vn.

AAPS Pharmscitech
|November 11, 2025
PubMed
Summary

This review explores advanced pharmaceutical formulations and analytical methods for donepezil, an Alzheimer's disease treatment. Innovations in drug delivery and quality control are crucial for improving patient outcomes and ensuring therapy effectiveness.

Keywords:
Alzheimer's diseaseDonepezilLiquid chromatographyNon-chromatographic techniquesNovel delivery systems

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.5K
Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers
09:25

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers

Published on: October 24, 2019

7.0K

Related Experiment Videos

Last Updated: Jan 11, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

781
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.5K
Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers
09:25

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers

Published on: October 24, 2019

7.0K

Area of Science:

  • Pharmaceutical Science
  • Analytical Chemistry
  • Neuroscience

Background:

  • Donepezil is a key acetylcholinesterase inhibitor for Alzheimer's disease (AD).
  • Evolving therapeutic needs necessitate advancements in drug quality, efficacy, safety, and patient compliance.
  • Pharmaceutical formulation and analytical methodologies are critical for optimizing AD treatment.

Purpose of the Study:

  • To review recent innovations in donepezil pharmaceutical formulations.
  • To summarize advancements in analytical methodologies for donepezil characterization and quality control.
  • To highlight the synergy between formulation and analytical science in enhancing donepezil therapy.

Main Methods:

  • Literature review focusing on pharmaceutical formulations and analytical techniques for donepezil.
  • Exploration of novel drug delivery systems (liposomes, nanoparticles, microneedles, nasal gels, depots).
  • Review of analytical methods including RP-HPLC, LC-MS/MS, chiral separations, electrochemistry, and spectroscopy.

Main Results:

  • Novel formulations aim to improve brain targeting, prolong release, and minimize side effects.
  • Advanced analytical methods enable precise quantification and characterization in various matrices.
  • Validated methods are essential for formulation performance evaluation, stability monitoring, and regulatory adherence.

Conclusions:

  • Progress in pharmaceutical formulation is key to developing enhanced donepezil delivery systems.
  • Advancements in analytical science are vital for ensuring the quality and efficacy of donepezil products.
  • Integrated development of formulation and analytical strategies is crucial for optimizing donepezil-based Alzheimer's disease management.